SCHEMBL7375645

SCHEMBL7375645

CCN(C(=O)OC(C)(C)C)c1ccccc1CN

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
LMNA P02545 3/20 0.35
CYP3A4 P08684 2/20 0.35
POLB P06746 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
NR1H2 P55055 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28261500 0.91 TSHR (0.41) TSHRALDH1A1GLALMNACYP3A4
SCHEMBL23498172 0.89 TAAR1 (0.37) TSHRALDH1A1GLALMNACYP3A4
SCHEMBL29723767 0.89 TAAR1 (0.37) TSHRALDH1A1GLALMNACYP3A4
SCHEMBL9729250 0.84 AKR1B1 (0.41) TSHRALDH1A1GLAHDAC3HDAC1
SCHEMBL16113033 0.84 ALDH1A1 (0.38) TSHRALDH1A1GLALMNACYP3A4
SCHEMBL7108590 0.82 CYP3A4 (0.37) TSHRALDH1A1GLACYP3A4GABRA1
SCHEMBL17077864 0.82 TSHR (0.39) TSHRALDH1A1GLALMNACYP3A4
SCHEMBL30443001 0.82 CYP3A4 (0.54) TSHRALDH1A1LMNACYP3A4POLB
SCHEMBL12117477 0.82 CYP3A4 (0.54) TSHRALDH1A1LMNACYP3A4POLB
SCHEMBL17086037 0.82 PAX8 (0.40) TSHRALDH1A1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002064211-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI TSHR 545/4885ALDH1A1 4773/4885GLA 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.